Published in Gene Therapy Weekly, November 7th, 2002
The agreement is expected to result in the shareholders of each company owning approximately 50% of the newly combined company, which plans to change its name to Autus Genetics Corp.
Autus is being created to capitalize on the complementary strengths of GenStar and VGI to accelerate the development of a later stage genetic therapy for cardiovascular disease as well as other therapies targeting important, unmet needs in major pharmaceutical market sectors.
Major benefits of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.